We are taking an entirely new approach to treating neurodegeneration,
targeting the elusive, fleeting protein intermediates that are central to many neurodegenerative disease pathways, and which are beyond the reach of conventional drug discovery approaches.
We have built a broad drug discovery platform to target the transient and unstable protein intermediates in amyloid disease pathways—toxic oligomers—with small-molecule drugs that interrupt the molecular mechanisms driving their formation.
We are focusing this platform first on two of the greatest unmet medical needs of our time: Alzheimer's and Parkinson’s diseases. Among the leading causes of death, Alzheimer’s is the only condition that cannot be cured, prevented, or even significantly slowed. And Parkinson’s is the fastest-growing neurological condition, afflicting more than 1 million people in the U.S. today, without any available disease-modifying therapy.